DK2920313T3 - Rekombinante adenovira og anvendelse deraf - Google Patents

Rekombinante adenovira og anvendelse deraf Download PDF

Info

Publication number: DK2920313T3
Authority: DK; Denmark
Prior art keywords: adenovira; recombinant; recombinant adenovira
Prior art date: 2012-11-16

Application number

DK13854932.4T

Other languages

English (en)

Inventor

Dan H Barouch

Herbert Virgin

Peter Abbink

Original Assignee

Beth Israel Deaconess Medical Ct Inc

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-16

Filing date

2013-11-15

Publication date

2019-09-02

2013-11-15 Application filed by Beth Israel Deaconess Medical Ct Inc, Univ Washington filed Critical Beth Israel Deaconess Medical Ct Inc

2019-09-02 Application granted granted Critical

2019-09-02 Publication of DK2920313T3 publication Critical patent/DK2920313T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Dermatology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pain & Pain Management (AREA)

DK13854932.4T 2012-11-16 2013-11-15 Rekombinante adenovira og anvendelse deraf DK2920313T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261727455P	2012-11-16	2012-11-16
PCT/US2013/070353 WO2014078688A2 (en)	2012-11-16	2013-11-15	Recombinant adenoviruses and use thereof

Publications (1)

Publication Number	Publication Date
DK2920313T3 true DK2920313T3 (da)	2019-09-02

Family

ID=50731831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13854932.4T DK2920313T3 (da)	2012-11-16	2013-11-15	Rekombinante adenovira og anvendelse deraf

Country Status (13)

Country	Link
US (2)	US10106781B2 (da)
EP (3)	EP2920313B1 (da)
JP (5)	JP2015536147A (da)
CN (3)	CN105051198A (da)
AU (2)	AU2013344512B2 (da)
CA (2)	CA2891349C (da)
DK (1)	DK2920313T3 (da)
ES (1)	ES3040856T3 (da)
IL (1)	IL238847B (da)
NZ (1)	NZ708144A (da)
SG (1)	SG11201503864TA (da)
WO (1)	WO2014078688A2 (da)
ZA (1)	ZA201503613B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SMT202000101T1 (it)	2008-10-10	2020-03-13	Childrens Medical Center	Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
CN105051198A (zh) *	2012-11-16	2015-11-11	貝丝以色列女执事医疗中心	重组腺病毒及其用途
CN105263506B (zh)	2013-01-07	2018-03-09	贝丝以色列女执事医疗中心	稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法
EP2946016A4 (en) *	2013-01-15	2016-11-23	Univ California	ADENOVIRES AND THEIR USE
US10376583B2 (en)	2013-09-30	2019-08-13	Beth Israel Deaconess Medical Center, Inc.	Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
EP3052518B1 (en)	2013-10-04	2020-01-08	Beth Israel Deaconess Medical Center, Inc.	Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same
WO2015128421A1 (en) *	2014-02-28	2015-09-03	Crucell Holland B.V.	Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
CA2961024A1 (en)	2014-09-26	2016-03-31	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CA3008542C (en)	2015-12-15	2020-06-02	Janssen Vaccines & Prevention B.V.	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
JP6595132B2 (ja)	2016-06-16	2019-10-23	ヤンセンファッシンズアンドプリベンションベーフェー	Ｈｉｖワクチン製剤
EP3472327B1 (en)	2016-06-20	2020-08-19	Janssen Vaccines & Prevention B.V.	Potent and balanced bidirectional promoter
CN110494159A (zh)	2016-09-02	2019-11-22	扬森疫苗与预防公司	在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
SG10202001956UA (en)	2016-09-15	2020-04-29	Janssen Vaccines & Prevention Bv	Trimer stabilizing hiv envelope protein mutations
WO2018075559A1 (en)	2016-10-17	2018-04-26	Beth Israel Deaconess Medical Center, Inc.	Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA3062591A1 (en)	2017-05-08	2018-11-15	Gritstone Oncology, Inc.	Alphavirus neoantigen vectors
EP3638302B1 (en)	2017-06-15	2024-03-13	Janssen Vaccines & Prevention B.V.	Poxvirus vectors encoding hiv antigens, and methods of use thereof
MY200554A (en)	2017-07-19	2024-01-03	Janssen Vaccines & Prevention Bv	Trimer stabilizing hiv envelope protein mutations
EP3713599A1 (en) *	2017-11-20	2020-09-30	Janssen Pharmaceuticals, Inc.	Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
WO2019118480A1 (en) *	2017-12-11	2019-06-20	Beth Israel Deaconess Medical Center, Inc.	Recombinant adenoviruses and uses thereof
EP3797118A4 (en)	2018-05-22	2022-06-29	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (hiv)
EP3836961A1 (en)	2018-08-13	2021-06-23	Janssen Vaccines & Prevention B.V.	Stabilized filovirus glycoprotein trimers
EP3867412A1 (en)	2018-10-15	2021-08-25	REGENXBIO Inc.	Method for measuring the infectivity of replication defective viral vectors and viruses
US12459989B2 (en)	2018-11-21	2025-11-04	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (HIV)
EP3886898A4 (en)	2018-12-01	2022-08-24	International AIDS Vaccine Initiative	RECOMBINATION HIV ENVELOPE POLYPEPTIDES AND THEIR USE
MX2021014525A (es) *	2019-05-30	2022-03-17	Gritstone Bio Inc	Adenovirus modificados.
BR112022016054A2 (pt) *	2020-02-14	2022-10-11	Altimmune Inc	Composições imunogênicas para coronavírus e usos das mesmas
US10894812B1 (en)	2020-09-30	2021-01-19	Alpine Roads, Inc.	Recombinant milk proteins
EP4222167A1 (en)	2020-09-30	2023-08-09	Nobell Foods, Inc.	Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en)	2020-09-30	2021-03-16	Alpine Roads, Inc.	Recombinant fusion proteins for producing milk proteins in plants
CN116867517A (zh)	2021-02-23	2023-10-10	扬森疫苗与预防公司	三聚体稳定性hiv包膜蛋白突变
WO2023156505A1 (en)	2022-02-17	2023-08-24	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
WO2023235763A1 (en)	2022-06-02	2023-12-07	Vector Sciences, Inc.	Method of reducing adenoviral vector-associated tts
WO2023250362A1 (en)	2022-06-21	2023-12-28	Regel Therapeutics, Inc.	Genetic regulatory elements and uses thereof
JP2024002411A (ja) *	2022-06-24	2024-01-11	株式会社三洋物産	遊技機
JP2024002412A (ja) *	2022-06-24	2024-01-11	株式会社三洋物産	遊技機
JP7605189B2 (ja) *	2022-06-24	2024-12-24	株式会社三洋物産	遊技機
WO2025083591A2 (en)	2023-10-17	2025-04-24	Regel Therapeutics, Inc.	Genetic regulatory elements for cardiac tissue expression and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US6054288A (en)	1991-11-05	2000-04-25	Transkaryotic Therapies, Inc.	In vivo protein production and delivery system for gene therapy
EP1445322B2 (en)	1995-06-15	2012-06-06	Crucell Holland B.V.	Packaging systems for human recombinant adenovirus to be used in gene therapy
EP1816204B1 (en)	1999-05-17	2010-10-20	Crucell Holland B.V.	Recombinant Adenovirus of the Ad26 serotype
US6492169B1 (en)	1999-05-18	2002-12-10	Crucell Holland, B.V.	Complementing cell lines
US20050232900A1 (en)	1999-05-18	2005-10-20	Crucell Holland B.V.	Serotype of adenovirus and uses thereof
EP1200622A4 (en)	1999-07-06	2004-12-22	Merck & Co Inc	HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
CA2422882A1 (en)	2000-09-15	2002-03-21	Merck & Co., Inc.	Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US20040136963A1 (en) *	2001-06-22	2004-07-15	The Trustees Of The University Of Pennsylvania	Simian adenovirus vectors and methods of use
EP1944043A1 (en)	2001-11-21	2008-07-16	The Trustees of the University of Pennsylvania	Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100987360B1 (ko)	2001-11-21	2010-10-12	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
WO2004001032A2 (en) *	2002-04-25	2003-12-31	Crucell Holland B.V.	Stable adenoviral vectors and methods for propagation thereof
WO2007104792A2 (en)	2006-03-16	2007-09-20	Crucell Holland B.V.	Recombinant adenoviruses based on serotype 26 and 48, and use thereof
PT2358757T (pt)	2008-11-18	2018-12-04	Beth Israel Deaconess Medical Ct Inc	Vacinas antivirais com imunogenicidade celular melhorada
SI2367943T1 (sl) *	2008-12-22	2017-07-31	Lek Pharmaceuticals D.D.	Sesalski ekspresijski vektor
MX2011007980A (es)	2009-02-02	2011-08-17	Okairos Ag	Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
BRPI1012951A2 (pt)	2009-06-09	2016-07-26	Defyrus Inc	"administração de interferon para profilaxia ou tratamento de infecção por patôgeno"
WO2011057254A2 (en) *	2009-11-09	2011-05-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Simian adenoviral vector-based vaccines
JP5980117B2 (ja) *	2009-11-09	2016-08-31	ジェンヴェック，インコーポレーテッド	サルアデノウイルスベクターの増殖方法
CN102844329B (zh)	2010-04-14	2016-01-20	财团法人牧岩生命工学研究所	分离自猿腺病毒血清型19的六邻体、其高变区和使用其的嵌合型腺病毒
WO2012021730A2 (en) *	2010-08-11	2012-02-16	Genvec, Inc.	Respiratory syncytial virus (rsv) vaccine
WO2013036791A2 (en) *	2011-09-09	2013-03-14	Beth Israel Deaconess Medical Center, Inc.	Modified adenoviral vectors and methods of treatment using same
CN105051198A (zh) *	2012-11-16	2015-11-11	貝丝以色列女执事医疗中心	重组腺病毒及其用途

2013
- 2013-11-15 CN CN201380068078.0A patent/CN105051198A/zh active Pending
- 2013-11-15 EP EP13854932.4A patent/EP2920313B1/en active Active
- 2013-11-15 JP JP2015542833A patent/JP2015536147A/ja active Pending
- 2013-11-15 CN CN202510766158.8A patent/CN121022880A/zh active Pending
- 2013-11-15 CA CA2891349A patent/CA2891349C/en active Active
- 2013-11-15 DK DK13854932.4T patent/DK2920313T3/da active
- 2013-11-15 SG SG11201503864TA patent/SG11201503864TA/en unknown
- 2013-11-15 CA CA3200425A patent/CA3200425A1/en active Pending
- 2013-11-15 AU AU2013344512A patent/AU2013344512B2/en active Active
- 2013-11-15 WO PCT/US2013/070353 patent/WO2014078688A2/en not_active Ceased
- 2013-11-15 EP EP19179450.2A patent/EP3564380B1/en active Active
- 2013-11-15 ES ES19179450T patent/ES3040856T3/es active Active
- 2013-11-15 CN CN202510771514.5A patent/CN120617493A/zh active Pending
- 2013-11-15 NZ NZ708144A patent/NZ708144A/en unknown
- 2013-11-15 US US14/443,299 patent/US10106781B2/en active Active
- 2013-11-15 EP EP25182744.0A patent/EP4631509A2/en active Pending
2015
- 2015-05-14 IL IL238847A patent/IL238847B/en unknown
- 2015-05-21 ZA ZA2015/03613A patent/ZA201503613B/en unknown
2018
- 2018-03-05 JP JP2018038380A patent/JP7011494B2/ja active Active
- 2018-09-17 AU AU2018229561A patent/AU2018229561B2/en active Active
- 2018-10-12 US US16/159,336 patent/US10781427B2/en active Active
2020
- 2020-07-10 JP JP2020119149A patent/JP7053728B2/ja active Active
2022
- 2022-03-31 JP JP2022057870A patent/JP2022101574A/ja active Pending
2024
- 2024-07-12 JP JP2024112088A patent/JP2024160183A/ja active Pending

Also Published As

Publication number	Publication date
NZ748353A (en)	2020-09-25
HK1215589A1 (en)	2016-09-02
JP2015536147A (ja)	2015-12-21
CA2891349A1 (en)	2014-05-22
EP4631509A2 (en)	2025-10-15
IL238847B (en)	2021-12-01
EP2920313A2 (en)	2015-09-23
US20190136205A1 (en)	2019-05-09
AU2018229561A1 (en)	2018-10-04
SG11201503864TA (en)	2015-06-29
EP2920313A4 (en)	2016-07-20
CA3200425A1 (en)	2014-05-22
WO2014078688A2 (en)	2014-05-22
US10781427B2 (en)	2020-09-22
CN121022880A (zh)	2025-11-28
EP3564380A1 (en)	2019-11-06
IL238847A0 (en)	2015-06-30
AU2018229561B2 (en)	2020-07-02
ES3040856T3 (en)	2025-11-05
AU2013344512B2 (en)	2018-06-28
CN105051198A (zh)	2015-11-11
JP7053728B2 (ja)	2022-04-12
US10106781B2 (en)	2018-10-23
JP7011494B2 (ja)	2022-01-26
AU2013344512A1 (en)	2015-05-28
ZA201503613B (en)	2019-09-25
EP2920313B1 (en)	2019-06-12
JP2018121636A (ja)	2018-08-09
JP2022101574A (ja)	2022-07-06
EP3564380B1 (en)	2025-06-18
US20150291935A1 (en)	2015-10-15
CA2891349C (en)	2023-07-18
NZ708144A (en)	2020-03-27
JP2020184997A (ja)	2020-11-19
JP2024160183A (ja)	2024-11-12
EP3564380C0 (en)	2025-06-18
WO2014078688A3 (en)	2014-07-03
CN120617493A (zh)	2025-09-12

Publication	Publication Date	Title
DK2920313T3 (da)	2019-09-02	Rekombinante adenovira og anvendelse deraf
DK2920197T3 (da)	2021-05-31	Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3346008T3 (da)	2021-01-11	Rekombinante mikroorganismer og anvendelser deraf
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2850202T3 (da)	2020-05-18	Fremgangsmåder og grupper
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
EP2870505A4 (en)	2016-03-09	TRANSPARENT GLOSS AND GLOSS PROTECTION STRUCTURES
DK3597644T3 (da)	2021-11-08	Kationiske aminlipider og anvendelser deraf
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK3550836T3 (da)	2022-01-10	Fremgangsmåde og anordning til afkodning
DK2920167T3 (da)	2020-01-20	Hydrazinyl-indol-forbindelser og konjugater
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3293183T3 (da)	2019-08-12	Hæmmerforbindelser
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK2552434T3 (da)	2019-06-11	Peptider og anvendelse deraf
DK2877576T3 (da)	2019-08-12	Xyloseisomeraser og anvendelser deraf
DK3058936T3 (da)	2019-05-13	Peptidsammensætning og anvendelser deraf
DK3003117T3 (da)	2020-12-07	Videolaryngoskop og laryngoskopindføringsdel
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3326642T3 (da)	2021-02-22	Langtidsvirkende koagulationsfaktorer og brugen deraf
EP2818054A4 (en)	2015-10-21	METHOD FOR COOKING STEAM NOODLES AND DEVICE FOR COOKING STEAM NOODLES
BR112014000049A2 (pt)	2017-02-07	pirrolotriazinas substituídas com hidroximelilarilo e sua utilização